Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial.
about
Immunobiology of hepatocarcinogenesis: Ways to go or almost there?Personalized Clinical Trials in Hepatocellular Carcinoma Based on Biomarker SelectionProgress in systemic therapy of advanced hepatocellular carcinomaHepatocellular carcinoma: Will novel targeted drugs really impact the next future?Molecularly targeted therapy for advanced hepatocellular carcinoma - a drug development crisis?Hepatobiliary Tumors: Update on Diagnosis and ManagementThe Role of Autophagy in Hepatocellular CarcinomaOptimal combination of antiangiogenic therapy for hepatocellular carcinomaHepatocellular carcinoma: Consensus, controversies and future directions. A report from the Canadian Association for the Study of the Liver Hepatocellular Carcinoma MeetingRecent advances in multidisciplinary management of hepatocellular carcinomaHepatocellular Cancer: New Kids on the BlockOncological Impact of M-Tor Inhibitor Immunosuppressive Therapy after Liver Transplantation for Hepatocellular Carcinoma: Review of the LiteratureEverolimus and Malignancy after Solid Organ Transplantation: A Clinical UpdateFirst- and Second-Line Targeted Systemic Therapy in Hepatocellular Carcinoma-An Update on Patient Selection and Response EvaluationAngiogenesis Inhibitors for the Treatment of Hepatocellular CarcinomaChallenges of advanced hepatocellular carcinomaHepatocellular Carcinoma: Therapeutic Guidelines and Medical TreatmentRecent advances in hepatocellular carcinoma therapy.Short-term and long-term efficacy of 7 targeted therapies for the treatment of advanced hepatocellular carcinoma: a network meta-analysis: Efficacy of 7 targeted therapies for AHCC.Comparison of hepatocellular carcinoma in Eastern versus Western populations.Regression of hepatocellular carcinoma after treatment of hepatitis C: a case report.Phase I/II study of temsirolimus for patients with unresectable Hepatocellular Carcinoma (HCC)- a correlative study to explore potential biomarkers for responsePhase II trial of everolimus in patients with refractory metastatic adenocarcinoma of the esophagus, gastroesophageal junction and stomach: possible role for predictive biomarkers.Phase I study of PF-03446962, a fully human monoclonal antibody against activin receptor-like kinase-1, in patients with hepatocellular carcinoma.A Phase I Study of Combination Therapy with Sorafenib and 5-Fluorouracil in Patients with Advanced Hepatocellular Carcinoma.Systemic therapy for advanced hepatocellular carcinoma: an update.Evolving role of Sorafenib in the management of hepatocellular carcinoma.The role of immunotherapy in solid tumors: report from the Campania Society of Oncology Immunotherapy (SCITO) meeting, Naples 2014Drug development for hepatocellular carcinoma: knowing the past helps to understand the futureRole of anti-angiogenesis therapy in the management of hepatocellular carcinoma: The jury is still out.Minimally invasive local therapies for liver cancerChemotherapy and target therapy for hepatocellular carcinoma: New advances and challenges.The over-expression of survivin enhances the chemotherapeutic efficacy of YM155 in human hepatocellular carcinoma.Epithelial to mesenchymal transition in the liver field: the double face of Everolimus in vitro.Neoadjuvant chemotherapy (NCT) plus targeted agents versus NCT alone in colorectal liver metastases patients: A systematic review and meta-analysisAdditive Anti-Tumor Effects of Lovastatin and Everolimus In Vitro through Simultaneous Inhibition of Signaling PathwaysLiver cancer: Approaching a personalized care.Determinants of survival after sorafenib failure in patients with BCLC-C hepatocellular carcinoma in real-world practiceHepatitis B virus reactivation in breast cancer patients undergoing chemotherapy: A review and meta-analysis of prophylaxis management.Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial.
P2860
Q26738293-9A4E4764-0CDA-4B35-A9A3-DA8BFD019FDAQ26738860-975AB82E-82E2-4C85-A683-B47CE6B77813Q26740217-32A57E54-4C99-4EBF-BC49-BF560C0C99F3Q26741201-11552700-C7F5-48FF-80E1-FF0778520D97Q26766689-1195020F-EF17-4060-9EF9-D6D9EA724E51Q26775654-1A48E2DC-609F-4BF3-92C8-D85C2432AD5DQ26777419-3011632D-30E5-4272-8CE4-1800DFBB235BQ26799458-28DD41CC-0310-427A-91F8-F301BDACF13FQ26828407-7A2236BD-1AFC-47B9-8FC1-5A68456CCFC9Q26863748-8396C2C2-1E68-4901-81FC-3F305C4EE4A4Q27022642-283497CB-D351-445F-BC32-AC79C9974BBDQ28067445-BFA727AD-6D26-4610-AF21-CE5964269361Q28067598-33888244-8451-44D2-8797-5B7A49F931FEQ28073654-E07E8820-F786-4C79-AE1A-D25CC9B14D81Q28075305-0C35AD1D-47E1-49D3-A79A-DDC7E0D7FF63Q28076867-3615D2F0-978B-4489-AD37-E2AD4EB2F3DEQ28079378-BE097B4E-93F3-4A19-B229-3815E20929F8Q30236010-417E80C1-67B8-4927-9328-F274F1912B28Q30240170-EBCC4DEB-7BE3-4915-A199-FE390279283EQ30245396-67C2BCDB-4CA0-4AB2-B872-C7F2A3B1567EQ30279258-CEF0A6C7-4463-48EF-8F44-5240008008F4Q33422744-A3394B90-DB66-4115-8449-CB0B21FAA575Q33422778-5CC91183-9B04-4626-83B7-94E3720C6357Q33433311-41FB7038-2454-477B-B77C-2079F73B59D4Q33442349-D80B4F2A-E334-4A36-98DE-63D92A6A70E0Q33593213-0C0ABA00-93DA-4C16-8E94-AFCB505DA7C3Q33779864-B59907DB-30B6-4243-9BA8-04A81AA8B705Q34402325-B97B733A-B1F3-4342-B667-F91882604F2CQ34458068-58C97566-0DA3-4F95-AF2F-AACCF25142D4Q34728237-40E43EEB-99E6-44BE-BD9C-AC2BE753D731Q34974386-2BFD736D-8D92-4C25-8C44-6E5693DF6E00Q35501246-ECA83388-21BF-49D1-B007-812FA1D573C6Q35742449-78F950D9-4CCD-4CEA-8881-352177E6DCDFQ35775057-5CB5251C-CB02-4EB2-B53C-ADB487B618DBQ35826810-1C8F4ADC-54EE-4FCC-8C22-560F8D589AEAQ35860831-B76B768F-52C1-4D50-811D-27C661361525Q35903794-F816A702-4FEE-4692-AD50-AD018598C009Q36009272-0D92AEDA-AFF2-4826-9899-356EF8209545Q36245362-A00C612D-5B40-41E1-BD0D-CD48CD5507ACQ36381360-5070380C-DD14-4481-81EA-1390E581E145
P2860
Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Effect of everolimus on surviv ...... E-1 randomized clinical trial.
@ast
Effect of everolimus on surviv ...... E-1 randomized clinical trial.
@en
Effect of everolimus on surviv ...... E-1 randomized clinical trial.
@nl
type
label
Effect of everolimus on surviv ...... E-1 randomized clinical trial.
@ast
Effect of everolimus on surviv ...... E-1 randomized clinical trial.
@en
Effect of everolimus on surviv ...... E-1 randomized clinical trial.
@nl
prefLabel
Effect of everolimus on surviv ...... E-1 randomized clinical trial.
@ast
Effect of everolimus on surviv ...... E-1 randomized clinical trial.
@en
Effect of everolimus on surviv ...... E-1 randomized clinical trial.
@nl
P2093
P50
P356
P1476
Effect of everolimus on surviv ...... E-1 randomized clinical trial.
@en
P2093
Andrew X Zhu
Annette Jappe
Arndt Vogel
Bruno Daniele
Chao-Long Chen
Dalila B Sellami
Eric Assenat
Etienne Dorval
Ho Yeong Lim
Jean-Frederic Blanc
P356
10.1001/JAMA.2014.7189
P407
P577
2014-07-01T00:00:00Z